Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052194 · ClinicalTrials.gov registry record · Phase 2
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
NCT01052194 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 206 participants.
The verdict
NCT01052194, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
Study Summary
This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients with active RA. The study will also evaluate the safety and tolerability of VX-509 compared to placebo when administered for 12 weeks to subjects with active RA.
Interventions
- DRUG Placebo
- DRUG VX-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052194
The ClinicalTrials.gov registry entry for NCT01052194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01052194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052194 about?
NCT01052194 is a clinical study titled "A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis". This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients with active RA. The study will...
What is the current status of trial NCT01052194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2010-02. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01052194?
The interventions under investigation include: Placebo (DRUG), VX-509 (DRUG).
Who is sponsoring clinical trial NCT01052194?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.